Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO
Portfolio Pulse from Benzinga Newsdesk
MediciNova announced that an abstract detailing the results of a clinical trial of MN-166 in glioblastoma has been accepted for presentation at the 2024 ASCO. The study, titled 'Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)', will be presented during the Rapid Oral Abstract session on Central Nervous System Tumors on June 2, 2024.
April 03, 2024 | 6:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MediciNova's announcement about the acceptance of an abstract for the 2024 ASCO presentation on MN-166's clinical trial results in glioblastoma could positively impact investor sentiment.
The acceptance of the abstract for presentation at a prestigious conference like ASCO highlights the potential significance of MN-166 in treating glioblastoma. This could lead to increased investor interest and optimism about the drug's prospects, potentially driving up MNOV's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100